Case Study in Cancer and Cardiotoxicity

Practice Based Evidence for Treatment of Pregnancy and Anthracycline Cardiomyopathy

Practice Based Evidence for Treatment of Pregnancy and Anthracycline Cardiomyopathy JEAN-BERNARD DURAND, M.D., FCCP, FACC,FACP,FHFSA,FAHA PROFESSOR OF MEDICINE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER

Can point of care cardiac biomarker testing guide cardiac safety during oncology trials?

Can point of care cardiac biomarker testing guide cardiac safety during oncology trials? Daniel J Lenihan, MD Professor, Division of Cardiovascular Medicine Director, Clinical Research Vanderbilt University

How to Evaluate the Heart of Elderly Patients

How to Evaluate the Heart of Elderly Patients Special considerations regarding cardiotoxicity Michael S. Ewer MD The University of Texas M. D. Anderson Cancer Center Why Discuss Cardiac Disease and Cancer

Chemotherapy- Associated Heart Failure. M. Birhan Yılmaz M.D, FESC Professor of Medicine Department of Cardiology Cumhuriyet University Sivas, TURKEY

Chemotherapy- Associated Heart Failure M. Birhan Yılmaz M.D, FESC Professor of Medicine Department of Cardiology Cumhuriyet University Sivas, TURKEY In last 20 years life-expectancy for patients with cancer

Advanced Echocardiography in the Evaluation of Chemotherapy Patients

Advanced Echocardiography in the Evaluation of Chemotherapy Patients Juan Carlos Plana, MD, FACC, FASE Co-Director, Cardio-Oncology Center Section of Cardiovascular Imaging Department of Cardiovascular

Cardiotoxicity: The View of the Cardiologist

Cardiotoxicity: The View of the Cardiologist Dr. Yael Peled, Cardio-Oncology Interactions: 1.Cardiotoxicity following chemotherapy 2. Co existence of cancer and CVD Aging & common risk factors cardiac

Cardio-Oncology at MHI. Kasia Hryniewicz, M.D.

Minneapolis Heart Institute at Abbott Northwestern Hospital Cardio-Oncology at MHI Cardiovascular Nursing Conference Kasia Hryniewicz, M.D. October 7 th, 2015 No disclosure 1 Why cardio-oncology? Background

Guideline-Driven Care in Cardio- Oncology: Utilizing Recommendations Across Disciplines

Guideline-Driven Care in Cardio- Oncology: Utilizing Recommendations Across Disciplines Jennifer Liu, MD FACC FASE Director of CV Laboratories Associate Professor of Clinical Medicine Memorial Sloan Kettering

Vasospasm and cardiac ischemia (Type 3 ) Hypertension Hypotension Arrhythmias Miscellaneous ( pericardial inflammation, valvular abnormalities )

Management of Cardiotoxicity due to Systemic Cancer Therapy Left Ventricular Dysfunction Type 1 cardiac dysfunction Type 2 cardiac dysfunction Vasospasm and cardiac ischemia (Type 3 ) Hypertension Hypotension

Disclosures. Objectives. SK continued. Two of my patients. First and foremost, why is this important??? 10/26/2016

Disclosures Bayer Pharmaceuticals: clinical trial investigator KellyAnn Light-McGroary, MD, FACC Clinical Assistant Professor Cardiomyopathy Treatment Program University of Iowa Hospitals and Clinics Chief

Cardio oncology Double Jeopardy

Cardio oncology Double Jeopardy Edie Pituskin RN MN (NP Adult) PhD NP Forum for Nursing and Allied Health, April 10, 2015 Aims Describe the double jeopardy faced by cancer patients Discuss issues in detection

Do we have to change our anti-cancer strategy in case of cardiac toxicity? Guy Jerusalem, MD, PhD

Do we have to change our anti-cancer strategy in case of cardiac toxicity? Point of view of the oncologist Guy Jerusalem, MD, PhD CHU Sart Tilman Liège Anticancer therapy: cardiac toxicity New anticancer

Cardiotoxicity from Chemotherapy : From Early Predictors to Therapeutics

Cardiotoxicity from Chemotherapy : From Early Predictors to Therapeutics Richard Sheppard MD FRCPC Director of Heart Failure Research Heart Function Clinic Jewish General hospital Objectives 1. Discuss

Potpourri: Cardio-Oncology Cases

Potpourri: Cardio-Oncology Cases Judy Hung, MD Massachusetts General Hospital Harvard Medical School No disclosures; Thank Michael Picard and Tomas Neilan for cases 59 year old woman (sister diagnosed

03/14/2019. Scope of the Problem. Objectives

Cardiac Consideration During and After Breast Cancer Treatment Indu G. Poornima M.D Division of Cardiology Scope of the Problem 1 in 8 women will develop breast cancer 3.3 million women are survivors CVD

CV Strategies to Mitigate Cardiotoxicity Pharmacologic Therapy Heart Failure Medications and Statins and For How Long

CV Strategies to Mitigate Cardiotoxicity Pharmacologic Therapy Heart Failure Medications and Statins and For How Long Ileana L. Piña, MD, MPH Professor of Medicine and Epidemiology/Population Health Albert

Cardio-oncology: Basics and Knowing When You Need an Echo

Cardio-oncology: Basics and Knowing When You Need an Echo Vera H. Rigolin, MD, FASE, FACC, FAHA Professor of Medicine Northwestern University Feinberg School of Medicine Medical Director, Echocardiography

Cured of Cancer but now Let s Heal the Heart An exploration into the effects of cancer on the heart

Cured of Cancer but now Let s Heal the Heart An exploration into the effects of cancer on the heart Suma H. Konety, MD, MS Associate Professor, Cardiovascular Division University of Minnesota What is Cardio-Oncology?

CARDIAC ISSUES IN CANCER SURVIVORS Jean-Bernard Durand, M.D.

CARDIAC ISSUES IN CANCER SURVIVORS Jean-Bernard Durand, M.D. Hello, my name is John-Bernard Durand. I m an Associate Professor of Medicine at University of Texas MD Anderson Cancer Center, and I ve been

Cardiotoxic Effects of Chemotherapy on Pediatric and Adult Survivors of Cancer

Cardiotoxic Effects of Chemotherapy on Pediatric and Adult Survivors of Cancer Dr. Chris Fryer, Pediatric Oncologist, BC Children s Hospital Dr. Sean Virani, Founding Director, UBC Cardiovascular Oncology

Cardio-oncology: Applying new echo technology to guide therapy

Cardio-oncology: Applying new echo technology to guide therapy Dinesh Thavendiranathan MD, SM, FRCPC, FASE Director, Ted Rogers Program in Cardiotoxicity Prevention Assistant Professor of Medicine Division

Susan P. D Anna MSN, APRN BC February 14, 2019

Is there Equal Opportunity in Heart Failure?? Susan P. D Anna MSN, APRN BC February 14, 2019 Disclosures: I have no financial disclosures. I am not an expert on this topic, but see a lot of women with

Renal Cell Cancer and TKIs:

Renal Cell Cancer and TKIs: What is my target BP? Should I use home monitoring? What is my target BP in cancer patients? Daniel J Lenihan, MD Professor, Division of Cardiovascular Medicine Director, Clinical

Anthracycline cardiomypathy in breast cancer: detection and prevention in high-risk patients

Anthracycline cardiomypathy in breast cancer: detection and prevention in high-risk patients Scottish Cancer Trials Breast Group Meeting Thursday 2 nd February 2017 Dr Peter Henriksen Edinburgh Heart Centre

Μυοκαρδιοπάθεια από τη θεραπεία του καρκίνου. Δημήτρης Φαρμάκης Ιατρική Σχολή ΕΚΠΑ Αθήνα

Μυοκαρδιοπάθεια από τη θεραπεία του καρκίνου Δημήτρης Φαρμάκης Ιατρική Σχολή ΕΚΠΑ Αθήνα Estimated and projected cancer survivors in USA de Moor JS et al. Cancer Epidemiol Biomarkers Prev 2013 Causes of

Redefining Cardiac Eligibility Thresholds in Oncology Trials. Role of Cardiovascular Core Labs

Redefining Cardiac Eligibility Thresholds in Oncology Trials. Role of Cardiovascular Core Labs Ana Barac, MD, PhD, FACC Associate Professor of Medicine, Georgetown University MedStar Heart and Vascular

New Cardiac Guidelines Where They Agree, Where They Differ, and How Does It Affect Patient Care

New Cardiac Guidelines Where They Agree, Where They Differ, and How Does It Affect Patient Care Sandra M Swain, MD, FACP, FASCO Professor of Medicine Associate Dean for Research Development Georgetown

Breast Cancer and the Heart

Breast Cancer and the Heart Anne H. Blaes, M.D., M.S. Associate Professor University of Minnesota Hematology/Oncology Director, Adult Cancer Survivor Clinic No disclosures Objectives Discuss cardiac complications

Cardio-Oncology: Advancing Cardiovascular Care of the Oncology Patient

Cardio-Oncology: Advancing Cardiovascular Care of the Oncology Patient Vijay U. Rao, MD, PhD, FACC, FASE Franciscan Physician Network Indiana Heart Physicians Director, Franciscan Health Inpatient Heart

Cardiac Toxicities Associated with Cancer Treatment

Cardiac Toxicities Associated with Cancer Treatment Hot Topics in Oncology Care 2017 Silicon Valley Oncology Nursing Society Christine Miaskowski, RN, PhD, FAAN American Cancer Society Clinical Research

Cancer survivors. Half of Cancer Survivors Die of Other Conditions. Cause of Death in Cancer Survivors

Cardiotoxicity of Cancer Therapies: Pathogenesis, Diagnosis, and Management Edward T.H. Yeh, M.D. Cancer survivors Now nearly 12 million cancer survivors in U.S. according to NCI 15% were diagnosed 2+

A Step Forward in Cancer Patient Care:

Hong Kong Pharmacy Conference 2018 A Step Forward in Cancer Patient Care: The Experience of Oncology Pharmacist-Managed Trastuzumab Clinic in Queen Mary Hospital Amy Yuen Clinical Pharmacist 24 Oct 2017.

Clinical history. 73 yo man with chest pain Systemic hypertension and WG Stress EKG N Stress echocardiogram: Cardiac catheterization: no CAD

CASE 8 Clinical history 73 yo man with chest pain Systemic hypertension and WG Stress EKG N Stress echocardiogram: Concentric hypertrophy Hypokinesis of LV-Inf Cardiac catheterization: no CAD Technique

Taxotere * and carboplatin plus Herceptin (trastuzumab) (TCH): the first approved non-anthracycline Herceptin-containing regimen 1

Important data from BCIRG 006 Taxotere * and carboplatin plus Herceptin (trastuzumab) (TCH): the first approved non-anthracycline Herceptin-containing regimen 1 in the adjuvant treatment of HER2+ breast

Cardiotoxicity Effects of Chemotherapeutic Drugs

Cardiotoxicity Effects of Chemotherapeutic Drugs Allan L Klein M.D. Director, Center of Pericardial Diseases Professor of Medicine Heart and Vascular Institute Cleveland Clinic President, ASE * No conflicts

UCLA-LIVESTRONG LIVESTRONG Survivorship Center of Excellence One in three individuals with receive a cancer diagnosis in their lifetime 10.6 million A

Cardiovascular Health After Cancer: Common and Overlooked Issues for Post-Cancer Care Barbara Natterson Horowitz, M.D. UCLA Division of Cardiology David Geffen School of Medicine at UCLA UCLA-LIVESTRONG

Risk of Subsequent Pregnancy in Women with a History of Peripartum Cardiomyopathy Uri Elkayam, MD

Risk of Subsequent Pregnancy in Women with a History of Peripartum Cardiomyopathy Uri Elkayam, MD Professor of Medicine / Cardiology Professor of Obstetrics and Gynecology University of Southern California

Congestive Heart Failure: Outpatient Management

The Chattanooga Heart Institute Cardiovascular Symposium Congestive Heart Failure: Outpatient Management E. Philip Lehman MD, MPP Disclosure No financial disclosures. Objectives Evidence-based therapy

Charles Spencer MD, FRCP Consultant Cardiologist Mid Staffs NHSFT

Charles Spencer MD, FRCP Consultant Cardiologist Mid Staffs NHSFT Key Messages Heart Failure is Common Heart failure is complex Heart Failure is a major issue for the NHS Heart Failure has a worse prognosis

Roohi Ismail-Khan, MD, MS

Roohi Ismail-Khan, MD, MS Associate Member Department of Breast Oncology H. Lee Moffitt Cancer Center Associate Professor University of South Florida Department of Oncological Sciences September 27, 2018

Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: ASCO Clinical Practice Guideline

Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: ASCO Clinical Practice Guideline J Clin Oncol. 2016 Dec 5:JCO2016705400. [Epub ahead of print] Objectives: Improve the quality

Anthracyclines in the elderly breast cancer patients

Anthracyclines in the elderly breast cancer patients Etienne GC Brain, MD PhD Medical Oncology Centre René Huguenin, Saint-Cloud & Group GERICO, FNCLCC, Paris Centre René Huguenin - Saint-Cloud Facts about

Outline. Pathophysiology: Heart Failure. Heart Failure. Heart Failure: Definitions. Etiologies. Etiologies

Outline Pathophysiology: Mat Maurer, MD Irving Assistant Professor of Medicine Definitions and Classifications Epidemiology Muscle and Chamber Function Pathophysiology : Definitions An inability of the

The Road to Improve Cardiovascular Health after Cancer. S. Carolina Masri, MD Cardiology Division University of Washington, Seattle June 2 nd 2018

The Road to Improve Cardiovascular Health after Cancer S. Carolina Masri, MD Cardiology Division University of Washington, Seattle June 2 nd 2018 Objective What are the cardiac complications in cancer

Pathophysiology: Heart Failure

Pathophysiology: Heart Failure Mat Maurer, MD Irving Assistant Professor of Medicine Outline Definitions and Classifications Epidemiology Muscle and Chamber Function Pathophysiology Heart Failure: Definitions

Ian Paterson, Mazankowski Alberta Heart Institute Division of Cardiology, University of Alberta

Ian Paterson, Mazankowski Alberta Heart Institute Division of Cardiology, University of Alberta Peer Reviewed Funding: CIHR, ACF, AI-HS Industry: Servier Canada Inc, RocheCanada Inc. What is your approach

BRLAACDT. Protocol Code. Breast. Tumour Group. Dr. Karen Gelmon. Contact Physician

BCCA Protocol Summary for Treatment of Locally Advanced Breast Cancer using DOXOrubicin and Cyclophosphamide followed by DOCEtaxel and Trastuzumab (HERCEPTIN) Protocol Code Tumour Group Contact Physician

Cycle 1 PERTuzumab (day 1) and trastuzumab (day 2) loading doses: Drug Dose BC Cancer Administration Guideline

BC Cancer Protocol Summary for Palliative Therapy for Metastatic Breast Cancer Using PERTuzumab, Trastuzumab (HERCEPTIN), and PACLItaxel as First-Line Treatment for Advanced Breast Cancer Protocol Code:

New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer

New Evidence reports on presentations given at ASCO 2012 New Targeted Agents Demonstrate Greater Efficacy and Tolerability in the Treatment of HER2-positive Breast Cancer Presentations at ASCO 2012 Breast

Representation of Patients with Cardiovascular Disease in Pivotal Cancer. Clinical Trials

Representation of Patients with Cardiovascular Disease in Pivotal Cancer Clinical Trials Running Title: Bonsu & Charles et al.; Cardiovascular Patients in Cancer Trials Janice Bonsu, MPH 1* ; Lawrence

CARDIOVASCULAR TOXICITY INDUCED BY ANTITUMOUR THERAPY. Florian SCOTTE, MDPhD Suresnes, France

CARDIOVASCULAR TOXICITY INDUCED BY ANTITUMOUR THERAPY Florian SCOTTE, MDPhD Suresnes, France DISCLOSURES Consultant / Advisory Boards / Speaker: Tesaro, Sanofi, Roche, MSD, TEVA, Norgine, Prostrakan, Leo

Multiparametric Mapping for Assessment of Cancer Therapy Related Cardiotoxicity

Multiparametric Mapping for Assessment of Cancer Therapy Related Cardiotoxicity Cory V. Noel, M.D. Medical Director of CMR Pediatric Cardiology Outline What is meant by the term cardiotoxicity? Scope of

CARDIOTOXICITY IN ONCOLOGY PRACTICE

CARDIOTOXICITY IN ONCOLOGY PRACTICE Evandro de Azambuja, MD, PhD Jules Bordet Institute, Brussels, Belgium CARDIOTOXICITY: THE MAGNITUDE OF THE PROBLEM Advances in cancer treatments have improved patients

Selective Cardiac Myosin Activators in Heart Failure

Selective Cardiac Myosin Activators in Heart Failure John McMurray Eugene Braunwald Scholar in Cardiovascular Diseases, Brigham and Women s Hospital, Boston & Visiting Professor, Harvard Medical School

Management Strategies for Advanced Heart Failure

Management Strategies for Advanced Heart Failure Mary Norine Walsh, MD, FACC Medical Director, HF and Cardiac Transplantation St Vincent Heart Indianapolis, IN USA President American College of Cardiology

Cased Based Approaches to Treatment of Pregnancy and Anthracycline Cardiomyopathy

Cased Based Approaches to Treatment of Pregnancy and Anthracycline Cardiomyopathy JEAN-BERNARD DURAND, M.D., FCCP, FACC,FACP,FHFSA,FAHA PROFESSOR OF MEDICINE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER

Cardiovascular Imaging Endpoints in Oncology Clinical Trials

Cardiovascular Imaging Endpoints in Oncology Clinical Trials Bonnie Ky, MD, MSCE Assistant Professor of Medicine and Epidemiology Director, Penn Cardio-Oncology Center of Excellence Director, Penn Center

Satish K Surabhi, MD.FACC,FSCAI,RPVI Medical Director, Cardiac Cath Labs AnMed Health Heart & Vascular Care

Satish K Surabhi, MD.FACC,FSCAI,RPVI Medical Director, Cardiac Cath Labs AnMed Health Heart & Vascular Care None Fig. 1. Progression of Heart Failure.With each hospitalization for acute heart failure,

Cancer and the heart: New evidence and open issues

Cancer and the heart: New evidence and open issues Dimitrios Farmakis, MD, PhD, FESC Assist. Professor, European University Cyprus Cardio-Oncology Clinic, Heart Failure Unit, Attikon Hospital Cardiac Clinic

Trastuzumab emtansine Kadcyla

Trastuzumab emtansine Kadcyla Indication Treatment of HER2 positive unresectable locally advanced or metastatic breast cancer for patients who have previously received a taxane and trastuzumab (Herceptin

Therapeutic Targets and Interventions

Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium

RECONCILING GUIDELINES, RECOMMENDATIONS AND CONSENSUS STATEMENTS TO PROVIDE OPTIMAL CARDIO-ONCOLOGY CARE

RECONCILING GUIDELINES, RECOMMENDATIONS AND CONSENSUS STATEMENTS TO PROVIDE OPTIMAL CARDIO-ONCOLOGY CARE SARO ARMENIAN, DO, MPH ASSOCIATE PROFESSOR, DEPARTMENTS OF PEDIATRICS AND POPULATION SCIENCES DIRECTOR,

Trastuzumab (IV) Monotherapy - 7 days

INDICATIONS FOR USE: Trastuzumab (IV) Monotherapy - 7 days Regimen *Reimbursement INDICATION ICD10 Code Status Treatment of patients with HER2 positive metastatic breast cancer (MBC) C50 00201a Hospital

Role of baseline echocardiography prior to initiation of anthracycline-based chemotherapy in breast cancer patients

Mina et al. BMC Cancer (2015) 15:10 DOI 10.1186/s12885-014-1004-0 RESEARCH ARTICLE Open Access Role of baseline echocardiography prior to initiation of anthracycline-based chemotherapy in breast cancer

BRAJACTT. Protocol Code. Breast. Tumour Group. Dr. Karen Gelmon. Contact Physician

BC Cancer Protocol Summary for Adjuvant Therapy for Breast Cancer using DOXOrubicin and Cyclophosphamide followed by PACLitaxel and Trastuzumab (HERCEPTIN) Protocol Code Tumour Group Contact Physician

Disclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017

Advances in Chronic Heart Failure Management Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017 I have nothing to disclose Disclosures 1 Goal statement To review recently-approved therapies

Research Article Clinical Experience of Patients Referred to a Multidisciplinary Cardiac Oncology Clinic: An Observational Study

Oncology Volume 2015, Article ID 671232, 5 pages http://dx.doi.org/10.1155/2015/671232 Research Article Clinical Experience of Patients Referred to a Multidisciplinary Cardiac Oncology Clinic: An Observational

Disclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17

Disclosures Advances in Chronic Heart Failure Management I have nothing to disclose Van N Selby, MD UCSF Advanced Heart Failure Program May 22, 2017 Goal statement To review recently-approved therapies

Congestive Heart Failure or Heart Failure

Congestive Heart Failure or Heart Failure Dr Hitesh Patel Ascot Cardiology Group Heart Failure Workshop April, 2014 Question One What is the difference between congestive heart failure and heart failure?

Managing HTN in the Elderly: How Low to Go

Managing HTN in the Elderly: How Low to Go Laxmi S. Mehta, MD, FACC The Ohio State University Medical Center Assistant Professor of Clinical Internal Medicine Clinical Director of the Women s Cardiovascular

Cardio-Oncology: Cardiac care specific to cancer patients and survivors. Learning Objectives

Cardio-Oncology: Cardiac care specific to cancer patients and survivors Lavanya Kondapalli MD, FACC Assistant Professor of Medicine, Division of Cardiology Director of Cardio-Oncology Learning Objectives

CASE STUDIES CLINICAL CASE SCENARIOS. Matthew J. Ellis, MD, PhD

CLINICAL CASE SCENARIOS Matthew J. Ellis, MD, PhD Clinicians face daily challenges in the management of individual patients with breast cancer who demonstrate different characteristics in terms of estrogen

BRAVTRAD. Protocol Code: Breast. Tumour Group: Dr. Susan Ellard. Contact Physician:

BCCA Protocol Summary for Palliative Therapy for Metastatic Breast Cancer using Trastuzumab (HERCEPTIN) and DOCEtaxel as First-Line Treatment for Advanced Breast Cancer Protocol Code: Tumour Group: Contact

Γυναίκα 67 ετών 2 η μετεγχειρητική ημέρα μετά αφαίρεση μονήρους πνευμονικού όγκου στον άνω λοβό του αριστερού πνεύμονα Οξύ πρόσθιο STEMI

Γυναίκα 67 ετών 2 η μετεγχειρητική ημέρα μετά αφαίρεση μονήρους πνευμονικού όγκου στον άνω λοβό του αριστερού πνεύμονα Οξύ πρόσθιο STEMI Οικογενειακό ιστορικό νεοπλασιών: αρνητικό Σύντομο ατομικό ιστορικό:

Association between RV Function in PPCM and LV Recovery & Clinical Outcome

Association between RV Function in PPCM and LV Recovery & Clinical Outcome Lori A Blauwet, MD, MA Associate Professor of Medicine Co-Director, Cardio-OB Clinic Mayo Clinic Rochester, MN USA 2016 MFMER

Δυναμική υπερηχοκαρδιογραφία στις μυοκαρδιοπάθειες : έχει θέση και ποια ;

Ελληνική Καρδιολογική Εταιρεία Σεμινάρια ομάδων εργασίας Θεσσαλονίκη, 8-10 Φεβρουαρίου 2018 Ομάδα εργασίας Ηχωκαρδιολογίας Δυναμική υπερηχοκαρδιογραφία στις μυοκαρδιοπάθειες : έχει θέση και ποια ; ΑΓΑΘΗ-ΡΟΖΑ

Incidence. 4.8 million in the United States. 400,000 new cases/year. 20 million patients with asymptomatic LV dysfunction

Heart Failure Diagnosis According to the Working Group in Heart Failure, CHF is a syndrome where the diagnosis has the following essential components: A combination of: Symptoms, typically breathlessness

Objectives. Let s start at the beginning 10/28/2014. What is Heart Failure? Understanding Heart Failure with Preserved LV Systolic Function

Understanding Heart Failure with Preserved LV Systolic Function Eric Ernst, MD Medical Director C.O.R.E. Clinic Objectives Clarify the terminology surrounding right heart failure and diastolic heart failure

Diastolic Heart Failure Uri Elkayam, MD

Diastolic Heart Failure Uri Elkayam, MD Professor of Medicine University of Southern California School of Medicine Los Angeles, California elkayam@usc.edu Diastolic Heart Failure Clinical Definition A

SIOG APAC th to 13 th July

SIOG APAC 2014 12 th to 13 th July Breast Cancer in Older Adults Cardiac Toxicity in Breast Cancer Dr Vivianne Shih, Pharm.D., BCPS, BCOP Specialist Pharmacist (Oncology) 1 Learning Objectives At the end

Protocol Identifier Subject Identifier Visit Description. [Y] Yes [N] No. [Y] Yes [N] N. If Yes, admission date and time: Day Month Year

PAST MEDICAL HISTORY Has the subject had a prior episode of heart failure? o Does the subject have a prior history of exposure to cardiotoxins, such as anthracyclines? URGENT HEART FAILURE VISIT Did heart

Survivorship: Managing Cardiac Toxicities

Survivorship: Managing Cardiac Toxicities Anecita Fadol, PhD, RN, FNP-BC, FAANP The University of Texas MD Anderson Cancer Center Learning Objectives Identify the causes of cardiac toxicity in cancer survivors

From PARADIGM-HF to Clinical Practice. Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group

From PARADIGM-HF to Clinical Practice Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group PARADIGM-HF: Inclusion Criteria Chronic HF NYHA FC II IV with LVEF

12/16/16. Cardio-oncology: A practical overview for the cardiologist. Disclosures. Learner Objectives. Case 1

Disclosures I have no relevant financial disclosures. Division of Cardiology Department of Medicine Rajni Rao, MD Associate Professor of Medicine Cardio-oncology: A practical overview for the cardiologist

Cosa c è di nuovo nelle LLGG e nella gestione del paziente con scompenso cardiaco. Maurizio Volterrani IRCCS San Raffaele Rome Capri, 24 April 2015

Cosa c è di nuovo nelle LLGG e nella gestione del paziente con scompenso cardiaco Maurizio Volterrani IRCCS San Raffaele Rome Capri, 24 April 2015 Treatment options for patients with chronic symptomatic

BC Cancer Protocol Summary for Adjuvant Therapy for Breast Cancer Using Weekly PACLitaxel and Trastuzumab (HERCEPTIN)

BC Cancer Protocol Summary for Adjuvant Therapy for Breast Cancer Using Weekly PACLitaxel and Trastuzumab (HERCEPTIN) Protocol Code: Tumour Group: Contact Physician: UBRAJTTW Breast Dr. Angela Chan ELIGIBILITY:

Building a Cardio-Oncology Program

Building a Cardio-Oncology Program Marielle Scherrer-Crosbie, MD, PhD Professor of Medicine Director of Echocardiography University of Pennsylvania Philadelphia, PA Co-Director, Cardio-Oncology Program

Original Article Left Ventricular Ejection in Cancer Patients Pak Armed Forces Med J 2014; 64 (3):468-72

Original Article Left Ventricular Ejection in Cancer Patients Pak Armed Forces Med J 2014; 64 (3):468-72 EARLY ASYMPTOMATIC DECLINE IN LEFT VENTRICULAR EJECTION FRACTION IN ADULT CANCER PATIENTS RECEIVING

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes

Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National

NCCP Chemotherapy Regimen

INDICATIONS FOR USE: Trastuzumab (IV) Monotherapy - 21 days Regimen *Reimbursement INDICATION ICD10 Code Status HER2 positive metastatic breast cancer (MBC) C50 00200a Hospital HER2 positive early breast

Heart failure and diabetes: SGLT-2 inhibition, a paradigm shift?

SGLT-2 inhibition, diabetes and CVD, ESC Rome August 28, 2016 Heart failure and diabetes: SGLT-2 inhibition, a paradigm shift? John McMurray BHF Cardiovascular Research Centre, University of Glasgow &

Updates in Congestive Heart Failure

Updates in Congestive Heart Failure GREGORY YOST, DO JOHNSTOWN CARDIOVASCULAR ASSOCIATES 1/28/2018 Disclosures Edwards speaker on Sapien3 valves (TAVR) Stages A-D and NYHA Classes I-IV Stage A: High risk

Drugs acting on the reninangiotensin-aldosterone

Drugs acting on the reninangiotensin-aldosterone system John McMurray Eugene Braunwald Scholar in Cardiovascular Diseases, Brigham and Women s Hospital, Boston & Visiting Professor, Harvard Medical School

PVCs: Do they cause Cardiomyopathy? Raed Abu Sham a, M.D.

PVCs: Do they cause Cardiomyopathy? Raed Abu Sham a, M.D. Cardiologist and Electrophysiologist No conflict of interest related to this presentation Objectives 1. PVCs are benign. What is the Evidence?

Desmin expression in cardiomyocytes - a good predictor of development of chronic heart failure.

Desmin expression in cardiomyocytes - a good predictor of development of chronic heart failure. Department of Invasive Cardiology, Central Hospital of Internal Affairs and Administration Ministry, Warsaw,

Advanced MR Imaging in Myocarditis

Naeem Merchant MD FRCP Professor of Medicine Department of Radiology Department of Cardiac Sciences Cumming School of Medicine University of Calgary Advanced MR Imaging in Myocarditis The Lake Louise Criteria

Revascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing

Revascularization in Severe LV Dysfunction: The Role of Inducible Ischemia and Viability Testing Evidence and Uncertainties Robert O. Bonow, MD, MS, MACC Northwestern University Feinberg School of Medicine

Stress Echocardiography: Illustrative Cases Sunil Mankad, MD, FACC, FCCP, FASE Associate Professor of Medicine Mayo Clinic College of Medicine Director, Transesophageal Echocardiography Associate Director,

BC Cancer Protocol Summary for Adjuvant Therapy for Breast Cancer Using DOCEtaxel, CARBOplatin, and Trastuzumab (HERCEPTIN)

BC Cancer Protocol Summary for Adjuvant Therapy for Breast Cancer Using DOCEtaxel, CARBOplatin, and Trastuzumab (HERCEPTIN) Protocol Code Tumour Group Contact Physician BRAJDCARBT Breast Dr. Susan Ellard

CardioOncology: The Promise and Pitfalls of Personalized Medicine

CardioOncology: The Promise and Pitfalls of Personalized Medicine Vijay U. Rao, MD, PhD, FACC, FASE, FHFSA Franciscan Physician Network Indiana Heart Physicians Director, Franciscan Health Inpatient Heart